financetom
Business
financetom
/
Business
/
Consulting firm McKinsey to pay $650 million to resolve US opioid probe
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Consulting firm McKinsey to pay $650 million to resolve US opioid probe
Dec 13, 2024 6:29 AM

BOSTON (Reuters) - McKinsey & Co has agreed to pay $650 million to resolve a U.S. Department of Justice investigation into the consulting firm's work advising opioid manufacturer OxyContin maker Purdue Pharma on how to boost sales.

McKinsey has entered into a deferred prosecution agreement filed in federal court in Abingdon, Virginia, to resolve criminal charges brought as part of a rare corporate prosecution concerning the marketing of addictive painkillers that helped fuel the deadly U.S. opioid epidemic.

A former senior partner at McKinsey, Martin Elling, has also agreed to plead guilty to obstruction of justice, according to court papers.

(Reporting by Nate Raymond in Boston)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Motor racing-Cadillac set clear targets for first year in F1
Motor racing-Cadillac set clear targets for first year in F1
Nov 19, 2025
LAS VEGAS, Nov 19 (Reuters) - Cadillac team boss Graeme Lowdon says Formula One's newest team will set out clear targets for their debut next season, focusing on execution and development rather than headline results. Speaking about his expectations, the team principal said it was impossible to set realistic championship targets before seeing how Cadillac's car compared with rivals. Next...
US FDA approves Bayer drug for specific type of lung cancer
US FDA approves Bayer drug for specific type of lung cancer
Nov 19, 2025
Nov 19 (Reuters) - The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung cancer that has advanced or spread despite earlier treatments. The drug, branded as Hyrnuo, is approved for non-squamous non-small cell lung cancer (NSCLC) in patients with mutations affecting the HER2 protein, which plays a...
Nvidia's strong forecast calms AI bubble jitters, for now
Nvidia's strong forecast calms AI bubble jitters, for now
Nov 19, 2025
By Arsheeya Bajwa and Stephen Nellis (Reuters) -Nvidia CEO Jensen Huang on Wednesday shrugged off concerns about an AI bubble as the company surprised Wall Street with accelerating growth after several quarters of slowing sales. The chipmaker's stellar third-quarter earnings and fourth-quarter forecast calmed, at least temporarily, investor nerves over concerns an AI boom has outrun fundamentals. Global markets have...
Nvidia's strong forecast calms AI bubble jitters, for now
Nvidia's strong forecast calms AI bubble jitters, for now
Nov 19, 2025
By Arsheeya Bajwa and Stephen Nellis (Reuters) -Nvidia CEO Jensen Huang on Wednesday shrugged off concerns about an AI bubble as the company surprised Wall Street with accelerating growth after several quarters of slowing sales. The chipmaker's stellar third-quarter earnings and fourth-quarter forecast calmed, at least temporarily, investor nerves over concerns an AI boom has outrun fundamentals. Global markets have...
Copyright 2023-2026 - www.financetom.com All Rights Reserved